COLLEGE PARK, Md. — An FDA panel Wednesday voted 12 to 1 that Acorda Therapeutics Inc.'s Phase III trials provided substantial evidence that fampridine sustained-release was effective in improving the walking ability in patients with multiple sclerosis. (BioWorld Today) Read More
